KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Cash from Financing Activities (2017 - 2025)

Amneal Pharmaceuticals has reported Cash from Financing Activities over the past 9 years, most recently at -$10.1 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at -$10.1 million for Q4 2025, up 83.47% from a year ago — trailing twelve months through Dec 2025 was -$31.5 million (up 85.11% YoY), and the annual figure for FY2025 was -$31.5 million, up 85.11%.
  • Cash from Financing Activities for Q4 2025 was -$10.1 million at Amneal Pharmaceuticals, down from $59.4 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for AMRX hit a ceiling of $59.4 million in Q3 2025 and a floor of -$100.8 million in Q4 2023.
  • Median Cash from Financing Activities over the past 5 years was -$36.6 million (2021), compared with a mean of -$35.0 million.
  • Biggest five-year swings in Cash from Financing Activities: tumbled 354.87% in 2023 and later skyrocketed 164.37% in 2025.
  • Amneal Pharmaceuticals' Cash from Financing Activities stood at -$30.4 million in 2021, then increased by 26.96% to -$22.2 million in 2022, then tumbled by 354.87% to -$100.8 million in 2023, then soared by 39.3% to -$61.2 million in 2024, then soared by 83.47% to -$10.1 million in 2025.
  • The last three reported values for Cash from Financing Activities were -$10.1 million (Q4 2025), $59.4 million (Q3 2025), and -$41.7 million (Q2 2025) per Business Quant data.